B. Riley Cuts Geron (NASDAQ:GERN) Price Target to $3.50

Geron (NASDAQ:GERN) had its price target lowered by B. Riley from $5.50 to $3.50 in a research report report published on Tuesday,Benzinga reports. B. Riley currently has a buy rating on the biopharmaceutical company’s stock. B. Riley also issued estimates for Geron’s FY2025 earnings at ($0.08) EPS, FY2026 earnings at $0.12 EPS and FY2027 earnings at $0.28 EPS.

A number of other research firms have also commented on GERN. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Geron in a research note on Tuesday, December 10th. Needham & Company LLC raised their target price on Geron from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, January 13th. Finally, Barclays raised Geron to a “strong-buy” rating in a report on Friday, November 29th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Geron has an average rating of “Moderate Buy” and a consensus price target of $6.91.

Geron Price Performance

Geron stock opened at $2.62 on Tuesday. The stock’s fifty day moving average price is $3.13 and its two-hundred day moving average price is $3.88. Geron has a one year low of $1.64 and a one year high of $5.34. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The firm has a market cap of $1.58 billion, a PE ratio of -8.17 and a beta of 0.53.

Institutional Investors Weigh In On Geron

Several hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new stake in shares of Geron during the 4th quarter valued at $45,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Geron by 24.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,267,176 shares of the biopharmaceutical company’s stock valued at $4,486,000 after acquiring an additional 246,433 shares in the last quarter. Woodline Partners LP boosted its holdings in shares of Geron by 64.6% during the 4th quarter. Woodline Partners LP now owns 11,587,344 shares of the biopharmaceutical company’s stock valued at $41,019,000 after acquiring an additional 4,549,031 shares in the last quarter. Velan Capital Investment Management LP acquired a new stake in shares of Geron during the 4th quarter valued at $173,000. Finally, Vestal Point Capital LP boosted its holdings in shares of Geron by 947.6% during the 4th quarter. Vestal Point Capital LP now owns 11,000,000 shares of the biopharmaceutical company’s stock valued at $38,940,000 after acquiring an additional 9,950,000 shares in the last quarter. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.